Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587805 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,672
- Enrollment target
NCT03587805 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 1,672 participants.
The verdict
NCT03587805, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,672 participants
- Enrollment target
Study Summary
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
Interventions
- DRUG Tralokinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,672 participants |
| Start Date | 2018-03-18 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03587805
The ClinicalTrials.gov registry entry for NCT03587805 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,672 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tralokinumab is the first listed.
NCT03587805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03587805 about?
NCT03587805 is a clinical study titled "Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND". The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
What is the current status of trial NCT03587805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,672 participants. The study started on 2018-03-18. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT03587805?
The interventions under investigation include: Tralokinumab (DRUG).
Who is sponsoring clinical trial NCT03587805?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.